<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01022359</url>
  </required_header>
  <id_info>
    <org_study_id>08/H0710/24</org_study_id>
    <nct_id>NCT01022359</nct_id>
  </id_info>
  <brief_title>Comparison of Tesio and LifeCath Twin Permanent Dialysis Catheters</brief_title>
  <acronym>VyTes</acronym>
  <official_title>Comparison of Tesio and LifeCath Twin Permanent Dialysis Catheters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College Healthcare NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare two available types of central venous haemodialysis catheters
      (lines) - CVCs, and will examine how easy they are to insert, complications, blood flow on
      dialysis over time, line loss, line clotting and infective events. It will examine whether
      the LifeCath type of CVC can deliver high blood flow rates from first use after insertion and
      equivalent function and complication rate to the Tesio type of CVC that is in use in our
      centre already. Complications relating to dialysis access make up 30% of admissions for
      haemodialysis patients and so this is a study that could benefit patients and their care
      providers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complications relating to dialysis access make up to 30% of admissions in haemodialysis
      patients. Comparative studies of complications between dialysis lines can help physicians and
      patients choose the best CVC type. In addition determining a type of dialysis line that can
      deliver good blood flows from the outset can minimise length of hospital stay for access
      creation. This study aims to perform a head-to-head comparison of two very similar (twin
      catheter) dialysis lines and examine short and long-term function as well as complication
      rates at our centre.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achieving a blood flow rate&gt;=450ml/min at first use after insertion</measure>
    <time_frame>First haemodialysis session after insertion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of flow rates&gt;=450ml/min at each dialysis session</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Line retention (either/both lumens)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infective episodes (catheter &amp; non-catheter related)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter dysfunction requiring use of thrombolytic agents</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications at catheter insertion</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recirculation rates</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Tesio Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomised to receive the established catheter type in use at our centre [control]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LifeCath</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TesioCath</intervention_name>
    <description>Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access</description>
    <arm_group_label>Tesio Catheter</arm_group_label>
    <other_name>BioFlex TesioCath (TM) - MedComp, Harleysville, PA, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LifeCath Twin</intervention_name>
    <description>Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access</description>
    <arm_group_label>LifeCath</arm_group_label>
    <other_name>Vygon LifeCath Twin - Vygon(UK) Ltd, Cirencester, Gloucs, UK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=18 years old

          -  No history of prior central venous catheter insertion

          -  Medically fit for procedure (able to lie flat, no haemodynamic instability)

          -  No active infection (recent positive blood cultures, clinical signs of infection,
             CRP&gt;100)

          -  Able to give informed consent

          -  Expected to survive more than 12 months after catheter insertion

        Exclusion Criteria:

          -  As above
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neill Duncan, MBBS MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College Healthcare NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Power, MBBChir MRCP</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College Healthcare NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Duncan ND, Singh S, Cairns TD, Clark M, El-Tayar A, Griffith M, Hakim N, Hamady M, McLean AG, Papalois V, Palmer A, Taube D. Tesio-Caths provide effective and safe long-term vascular access. Nephrol Dial Transplant. 2004 Nov;19(11):2816-22. Epub 2004 Aug 31.</citation>
    <PMID>15340094</PMID>
  </reference>
  <reference>
    <citation>Perini S, LaBerge JM, Pearl JM, Santiestiban HL, Ives HE, Omachi RS, Graber M, Wilson MW, Marder SR, Don BR, Kerlan RK Jr, Gordon RL. Tesio catheter: radiologically guided placement, mechanical performance, and adequacy of delivered dialysis. Radiology. 2000 Apr;215(1):129-37.</citation>
    <PMID>10751478</PMID>
  </reference>
  <reference>
    <citation>Hassell DD 3rd, Vesely TM, Pilgram TK, Audrain JL. Initial performance of Tesio hemodialysis catheters. J Vasc Interv Radiol. 1999 May;10(5):553-8.</citation>
    <PMID>10357479</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>haemodialysis</keyword>
  <keyword>vascular access</keyword>
  <keyword>central venous catheter</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

